AGENUS INC
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
AGEN$7.02-1.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Income (Loss)
(Amounts in thousands, except per share amounts)
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue: | |||
| Research and development | $334 | $482 | $38,764 |
| Pre-commercial product revenue | 4,238 | — | — |
| Service revenue | 1,036 | 2,003 | 2,978 |
| Non-cash revenue related to the sale of future royalties | 108,588 | 100,978 | 114,572 |
| Total revenues | 114,196 | 103,463 | 156,314 |
| Operating expenses: | |||
| Cost of revenue | (1,022) | (486) | (3,111) |
| Research and development | (79,338) | (155,528) | (234,569) |
| General and administrative | (54,392) | (71,878) | (78,739) |
| Fair value adjustments | 387 | 3,954 | 556 |
| Operating loss | (20,169) | (120,475) | (159,549) |
| Other income (expense): | |||
| Non-operating income (expense) | (2,220) | 5,830 | 37 |
| MiNK Therapeutics, Inc. equity method investment fair value adjustment | (26,345) | — | — |
| Gain from deconsolidation of MiNK Therapeutics, Inc. | 100,924 | — | — |
| Interest expense, net | (55,273) | (117,626) | (97,925) |
| Net loss | (3,083) | (232,271) | (257,437) |
| Dividends on Series A-1 convertible preferred stock | (216) | (215) | (213) |
| Less: net loss attributable to non-controlling interest | (3,198) | (5,059) | (11,676) |
| Net loss attributable to Agenus Inc. common stockholders | $(101) | $(227,427) | $(245,974) |
| Per common share data: | |||
| Basic and diluted net loss attributable to Agenus Inc. common stockholders | $(0.00) | $(10.59) | $(13.75) |
| Weighted average number of Agenus Inc. common shares outstanding: | |||
| Basic and diluted | 29,734 | 21,473 | 17,894 |
| Other comprehensive income (loss): | |||
| Foreign currency translation gain (loss) | $959 | $(443) | $(1,870) |
| Other comprehensive income (loss) | 959 | (443) | (1,870) |
| Comprehensive income (loss) | $858 | $(227,870) | $(247,844) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.